# EDGAR Filing Document

**Accession Number:** 0001810560
**File Stem:** 0000950170-23-000759
**Filing Date:** 2023-1
**Character Count:** 5714
**Document Hash:** 720d143676b0891e0d8732de0eedf8bd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-23-000759.hdr.sgml**: 20230113

**ACCESSION NUMBER**: 0000950170-23-000759

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230113

**DATE AS OF CHANGE**: 20230113

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** REVELATION BIOSCIENCES, INC.
- **CENTRAL INDEX KEY:** 0001810560
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 843898466
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39603
- **FILM NUMBER:** 23529078

**BUSINESS ADDRESS:**
- **STREET 1:** 4660 LAJOLLA VILLAGE DRIVE
- **STREET 2:** SUITE 100
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92122
- **BUSINESS PHONE:** 650-800-3717

**MAIL ADDRESS:**
- **STREET 1:** 4660 LAJOLLA VILLAGE DRIVE
- **STREET 2:** SUITE 100
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92122

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Petra Acquisition Inc.
- **DATE OF NAME CHANGE:** 20200423

**UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION<br>Washington, D.C. 20549**

**________________**

**SCHEDULE 14A**

**Proxy Statement Pursuit to Section 14(a) of the** 

**Securities Exchange Act of 1934**

**(Amendment No. 1)**

**________________**

Filed by the Registrant ☒ <br> Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ Confidential, for the use of the Commission only (as permitted by Rule 14a-6(e)(2))

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material Pursuant to §240.14a-12

**REVELATION BIOSCIENCES, INC.<br>(Name of Registrant as Specified in its Charter)**

**_________________________________________________________________**

**(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)**

Payment of Filing Fee (Check the appropriate box):

☒ No fee required.

☐ Fee paid previously with preliminary materials.

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11.

------

![img54250246_0.jpg](img54250246_0.jpg)

**<u>Revelation Biosciences, Inc. announces adjournment of Special Meeting of Stockholders</u>**

Revelation Biosciences, Inc. announced that the Special Meeting of Stockholders is being adjourned to January 30, 2023 to provide stockholders with additional time to vote on the proposals to approve an amendment to the amended and restated Company's Certificate of Incorporation to authorize additional shares of common stock, to effect a reverse stock split, and to ratify the appointment of Baker Tilly US, LLP as the Company's independent registered public accountants. You may refer to the proxy statement previously filed with the SEC for any additional information

Your vote is very important. The Board of Directors recommends you vote in support of the proposals.

The Board believes that the availability of additional authorized shares of common stock is required for several reasons including, but not limited to, the additional flexibility to issue common stock for a variety of general corporate purposes as the Board may determine to be desirable including, without limitation, future financings, investment opportunities, acquisitions, or other distributions and stock splits (including splits effected through the declaration of stock dividends).

The Board believes that effecting the Reverse Stock Split would increase the price of our common stock which would, among other things, help us to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪Meet certain listing requirements of the Nasdaq Capital Market;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪Appeal to a broader range of investors to generate greater interest in the Company; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪Improve perception of our common stock as an investment security.

Since these proposals require an affirmative vote of a majority of the outstanding shares for passage, by not responding with your vote you are essentially opposing these proposals.

Therefore, we urge our stockholders who have not yet executed their vote to please do so.

**Please vote your shares of stock now so that your vote can be counted without delay.** Voting is easy. You may use one of the options below to ensure that your vote is promptly recorded in time for the Special Meeting:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪**<u>VOTE BY TOUCH-TONE PHONE:</u>** You may cast your vote by calling the toll-free number on the enclosed proxy card. Follow the instructions on your proxy card to cast your vote.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪**<u>VOTE VIA THE INTERNET:</u>** You may cast your vote by logging onto the website identified on the enclosed proxy card and following the instructions on the screen.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪**<u>VOTE BY MAIL:</u>** You may cast your vote by mail by completing, signing, dating, and mailing the enclosed proxy card in the prepaid postage return envelope provided.

If you have any questions or require further assistance in voting your shares, please contact our proxy solicitation agent Advantage Proxy toll-free at 877-870-8565.

Sincerely,

/s/ James Rolke

**James Rolke**

**Director and Chief Executive Officer**

**IF YOU HAVE RECENTLY MAILED YOUR PROXY CARD OR CAST YOUR VOTE BY PHONE OR INTERNET,** <br>**PLEASE ACCEPT OUR THANKS AND DISREGARD THIS REQUEST.**<br>

------